Overview of Dr. Cherng
Dr. Hua-Jay Cherng is a New York-based oncologist with a subspecialty in hematologic oncology. He has been educated and trained at prestigious institutions, starting at Case Western Reserve University School of Medicine, followed by his internship and residency at University of Pennsylvania Health System, and his fellowship at University of Texas Health Science Center at Houston/M D Anderson Cancer Center. Professional experience ranges from Resident Physician at the Hospital of the University of Pennsylvania to Clinical Fellow at University of Texas M.D. Anderson Cancer Center. His expertise lies in internal medicine and medical oncology. He has an impressive list of publications in esteemed journals, discussing various aspects of lymphoma, DLBCL treatment, and CAR T-cell therapy.
Office
161 Fort Washington Ave
New York, NY 10032
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
- University of Pennsylvania Health SystemInternship, Internal Medicine, 2016 - 2019
- Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2016 - 2019
- Case Western Reserve University School of MedicineClass of 2016
Certifications & Licensure
- NY State Medical License 2022 - 2025
- TX State Medical License 2019 - 2024
- PA State Medical License 2018 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsCirculating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?Hua-Jay J Cherng, Alex Herrera
Current Treatment Options in Oncology. 2024-05-01 - Measurable Residual Disease Monitoring in Lymphoma.Brian Cuzzo, Andrew Lipsky, Hua-Jay J Cherng
Current Hematologic Malignancy Reports. 2023-12-01 - 10 citationsA phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.Hua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, Loretta J Nastoupil, Luis Fayad
Blood Advances. 2023-04-11
Press Mentions
- Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma PatientsDecember 5th, 2024
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: